FPMI (FluoroPharma Medical) Beta: -68.2978 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Beta?

FluoroPharma Medical FPMI Beta is -68.2978 as of Aug. 02, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-02), FluoroPharma Medical's Beta is -68.2978.


FluoroPharma Medical  (OTCPK:FPMI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


FluoroPharma Medical Beta Related Terms


FluoroPharma Medical Beta Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Beta Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.03 -0.22 -0.10 0.56

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 0.48 0.43 0.65 0.56

FPMI vs HSTC, OBMPD, GOVX: Beta Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Beta distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Beta falls into.



FluoroPharma Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -68.2978 mean?
FluoroPharma Medical (FPMI) has a Beta of -68.2978 as of Aug. 02, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Beta too high?
FluoroPharma Medical's current Beta is -68.2978.
How does FluoroPharma Medical's Beta compare to HSTC and OBMPD?
FluoroPharma Medical's Beta of -68.2978 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for FluoroPharma Medical and its competitors. FluoroPharma Medical's current Beta is -68.2978. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Beta of -68.2978. The current Beta is -68.2978. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Beta is -68.2978 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.